Sickle Cell Disease Speaker Series Schedule


1	Date	Speaker		Title	Affiliation

2	Upcoming:
3
4	3/10/2025	Martha Kenney, MD		Nociplastic Pain in Sickle Cell Disease: Is it the Missing Piece of the Puzzle?	Duke University School of Medicine
5	4/25/2025	TBD		TBD	TBD
6
7	Past talks:
8
9	1/13/2025	Swee Lay Thein, MD, DSc, FMedSci		Activating pyruvate kinase in Sickle Cell Disease	National Institutes of Health (NIH)
10	2/10/2025	David A. Williams, MD		Recent Developments in Gene Therapy	Harvard Medical School
11	10/14/2024	Sarah O'Brien, MD, MSc		Hormonal Contraceptive in Patients Living with Sickle Cell Disease: Benefits, Risks and All the Unknowns in Between	Nationwide Children's Hospital
12	11/11/2024	Ann Kinga Malinowski, MD, MSc, FRCSC		Sickle Cell Disease in Pregnancy	Sinai Health System
13	7/8/2024	Erica Sparkenbaugh, PhD		Tipping the Balance – Inducing Protective PAR1 Signaling in Sickle Cell Disease	University of North Carolina at Chapel Hill, Blood Research Center
14	6/10/2024	Charles Quinn, MD, MS		Current Therapeutics for Pediatric SCD	Cincinnati Children's Hospital Medical Center
15	3/11/2024	Eugenia Vicky	Asare, MBChB	The Power of Multidisciplinary Expertise: Lessons from the Korle-Bu Teaching Hospital, Accra, Ghana	Ghana Institute of Clinical Genetics, Korle-Bu Teaching Hospital
16	2/12/2024	Zena	Quezado, MD	Ketamine as an Adjuvant to Opioids in Sickle Cell Pain	National Institutes of Health
17	1/8/2024	Julie	Kanter, MD	Gene Therapies for Sickle Cell Disease
18	11/13/2023	Rafaella	Colombatti, MD, PhD	SCD Data Collection in Europe: challenges and opportunities
19	10/9/2023	Lachelle	Weeks, MD, PhD	Risk Stratification in Clonal Hematopoiesis – Implications for Curative Therapy in Sickle Cell Disease
20	9/11/2023	Monica	Hulbert, MD	5th Annual SiNERGe Symposium Keynote Speech
21	7/10/2023	Satheesh	Chonat, MD	Complement in Sickle Cell Disease
22	6/12/2023	Pat	Carroll, MD	[Buprenorphine]
23		Sophie	Lanzkron, MD, MHS
24	5/8/2023	Luke	Smart, MD	TCD screening and stroke prevention in sub-Saharan Africa
25	3/13/2023	Jane	Little, MD	Hypoxia at night: who has it? What does it mean?
26	2/13/2023	Stella	Chou, MD	RH genotyping to improve red cell matching for individuals with SCD
27	1/9/2023	Erica	Esrick, MD	Gene therapy for sickle cell disease
28	12/19/2022*	Umut	Gurkan, PhD	Microfluidic Imaging Systems for Single-Cell Level Mechanobiology and Biophysics Studies of Blood Cells
29	11/14/2022	Veronica	Carullo, MD, FAAP	Beyond the crisis: What's new in pain management in sickle cell disease?
30		& Kerry	Morrone, MD
31	10/10/2022	Brian	Laurence, DDS, PhD	Oral health and sickle cell disease: the role of access to care
32	9/12/2022	Joshua	Field, MD, MS	The Role of Circulating Fibrocytes in Sickle Cell Lung Disease
33	August	-summer	break-
34	July	-summer	break-	-
35	6/13/2022	Ambroise	Wonkam, PhD	The Genomics Keys of Sickle-Cell Disease Therapeutics
36	5/9/2022	Courtney	Fitzhugh, MD	Clonal Hematopoiesis Following Curative Therapies for Sickle Cell Disease
37	4/11/2022	Mary	Eapen, MRCPI, MS, MBBS	Hematopoietic cell transplant for sickle cell disease: Built to last?
38	3/14/2022	Andrew	Heitzer, PhD	Neuropsychological Functioning in Sickle Cell Disease: Risk and Protective Factors
39	2/14/2022	Arthur	Burnett, MD	New Management Paradigm for Recurrent Ischemic Priapism
40	1/17/2022	Eugene	Oteng-Ntim, MBBs MRCOG PGDip FRCOG	Sickle Cell disease in Pregnancy: When the miracle of childbirth becomes a matter of life and death
41	11/8/2021	William	Zempsky, MD, MPH	Drowning in a sea of pain: Chronic pain in sickle cell disease
42	10/11/2021	Karina	Yazdanbakhsh, PhD	Hemolysis and immune activation in sickle cell disease
43	9/13/2021	Venée	Tubman, MD, MMSc	The Spleen in Sickle Cell Disease: Gone but Not Forgotten
44	7/12/2021	Marcus	Carden, MD	Emergency department use of intravenous fluids and outcomes in pediatric and adult patients with sickle cell disease: from the bench and bedside
45	6/14/2021	Wally	Smith, MD	Race, Science, and Medicine
46	5/10/2021	Guillaume	Lettre, PhD	A Genetic Perspective on Clinical Heterogeneity in Sickle Cell Disease
47	4/12/21	Swee Lay	Thein, M.B., B.S., F.R.C.P., F.R.C.Path., D.Sc., FMedSci	Utilizing AI and machine learning to derive A Phenotypic Risk Score for Prediction of Mortality in Sickle Cell Disease
48		Xin	Tian, PhD
49		Vandana	Sachdev, MD
50	3/8/2021	Mark	Walters, MD	Curative Therapies for Sickle Cell Disease
51	2/8/2021	Patrick	McGann, MD MS	Optimization of Hydroxyurea Use through Precision Medicine: Experience in Children and Next Steps for Adults
52	1/25/2021	Claudia	Morris, MD	New Perspectives on Arginine Therapy in Sickle Cell Disease
53	11/9/2020	Mitchell	Weiss, MD PhD	Genome Editing for Sickle Cell Disease
54	10/26/2020	Kalpna	Gupta, PhD	Pain in Sickle Cell Disease: Working Towards the Challenge
55	10/12/2020	Lydia	Pecker, MD	From Anecdote to Data: Fertility and Fertility Preservation in Girls and Women with SCD
56	9/28/2020	Jeffrey	Lebensburger, MD	Pediatric Renal Manifestations of Sickle Cell Disease
57	9/14/2020	Roberto	Machado, MD	Understanding Pulmonary Complications of Sickle Cell Disease: A Precision Medicine Approach
58	8/31/2020	Melanie	Fields, MD	Using MRI to Understand the Impact of Sickle Cell Anemia on Brain Development
59	8/24/2020	Thomas	Coates, MD	Iron Overload, the Short and the Long of it: Lessons from Rare Transfusion Dependent Anemias
60	8/17/2020	Santosh	Saraf, MD	Sickle Cell Nephropathy
61		& Vimal	Derebail, MD, MPH, FASN	Sickle Cell Nephropathy
62	8/3/2020	Caterina	Minniti, MD	Leg Ulcers in sickle Cell Disease: approaches to management
63	7/27/2020	John	Tisdale, MD	Toward curative therapies for sickle cell disease, where do we stand?
64	7/20/2020	Theodore	Wun, MD, FACP	Thick and Thin: Clotting and Bleeding in Patients with Sickle Cell Disease
65	7/13/2020	Kenneth	Ataga, MD	The Evolving Landscape of Drug Therapies in Sickle Cell Disease
66	7/6/2020	JJ	Strouse, MD, PhD	Functional Assessment for Adults with Suckle Cell Disease
67	6/29/2020	Jane	Hankins, MD, MS	What transition to adult care can teach us about cohort studies in SCD
68	6/22/2020	John C.	Wood, MD, PhD	Pathophysiology of white matter damage in Sickle Cell Disease: Challenges and Controversies
69	6/15/2020	Marsha	Treadwell, PhD	Patient Reported Outcome Measures in Sickle Cell Disease
70	6/8/2020	Dan	Bauer, MD, PhD	Gene Editing for Sickle Cell Disease
71	6/1/2020	Marcus	Bankes, BSc, FRCS	Avascular Necrosis in Sickle Cell Disease
72	5/18/2020	Vivien	Sheehan, MD, PhD	Red Cell Rheology: Biomarkers to evaluate sickle cell disease therapies
73	5/11/2020	Allison	King, MD, MPH, PhD	Cognitive Health and Sickle Cell Disease: Screen to Intervene
74	5/4/2020	Jo	Howard, MB Bchir, MRCP, FRCPath	An update on transfusion in sickle cell disease: ASHguidelines and (a little) on COVID-19
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92	x